AG2R LA Mondiale Gestion D Actifs Buys Shares of 9,677 Insmed, Inc. $INSM

Posted by Linda Flegge on May 13th, 2026

AG2R LA Mondiale Gestion D Actifs bought a new stake in shares of Insmed, Inc. (NASDAQ:INSM – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 9,677 shares of the biopharmaceutical company’s stock, valued at approximately $1,684,000.

Other hedge funds also recently made changes to their positions in the company. CoreCap Advisors LLC acquired a new position in shares of Insmed in the 4th quarter worth approximately $27,000. GraniteShares Advisors LLC acquired a new position in shares of Insmed in the 4th quarter worth approximately $30,000. CIBC Private Wealth Group LLC grew its stake in shares of Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 53 shares during the last quarter. SBI Securities Co. Ltd. grew its stake in shares of Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 166 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. grew its stake in shares of Insmed by 169.7% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 151 shares during the last quarter.

Insmed Stock Performance

INSM stock opened at $116.00 on Wednesday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.10 and a current ratio of 4.47. The stock has a market cap of $25.14 billion, a P/E ratio of -20.17 and a beta of 0.89. The firm has a 50 day simple moving average of $143.34 and a 200 day simple moving average of $164.25. Insmed, Inc. has a 52 week low of $64.85 and a 52 week high of $212.75.

Insmed (NASDAQ:INSM – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.14. The business had revenue of $305.96 million during the quarter, compared to analysts’ expectations of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The firm’s quarterly revenue was up 229.7% compared to the same quarter last year. During the same period last year, the company posted ($1.42) earnings per share. Research analysts anticipate that Insmed, Inc. will post -2.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Stifel Nicolaus lifted their price objective on shares of Insmed from $205.00 to $208.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Mizuho lifted their price objective on shares of Insmed from $204.00 to $206.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 25th. HC Wainwright reaffirmed a “buy” rating on shares of Insmed in a research note on Friday. Jefferies Financial Group assumed coverage on shares of Insmed in a research note on Monday, March 16th. They issued a “buy” rating and a $228.00 price objective on the stock. Finally, Royal Bank Of Canada lowered their price objective on shares of Insmed from $220.00 to $205.00 and set an “outperform” rating on the stock in a research note on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $211.86.

Read Our Latest Stock Report on INSM

Key Stories Impacting Insmed

Here are the key news stories impacting Insmed this week:

Positive Sentiment: Investors stepped in to buy the dip after Insmed hit a 10-month low, helping the shares rebound sharply from recent weakness. Insmed (INSM) Soars on Bargain-Hunting After 10-Month Low
Positive Sentiment: HC Wainwright kept a Buy rating and raised its near-term earnings estimates for Insmed’s Q2, Q3, and FY2026 results, which may support sentiment around the company’s growth outlook. MarketBeat Insmed estimate updates
Neutral Sentiment: Insmed presented at the Bank of America Global Healthcare Conference, which may have added visibility but no clear new catalyst was highlighted in the transcript. Insmed Presents at Bank of America Global Healthcare Conference 2026 Transcript
Negative Sentiment: HC Wainwright trimmed longer-term earnings estimates for FY2027 through FY2030, signaling some caution about Insmed’s profit trajectory beyond the near term. MarketBeat Insmed estimate updates

Insider Buying and Selling

In related news, COO Roger Adsett sold 88,060 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the completion of the sale, the chief operating officer directly owned 106,810 shares in the company, valued at approximately $17,584,130.30. This trade represents a 45.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Michael Alexander Smith sold 19,638 shares of the firm’s stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the sale, the insider owned 51,871 shares of the company’s stock, valued at approximately $7,831,483.58. This represents a 27.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 161,193 shares of company stock worth $25,462,012. 2.10% of the stock is owned by company insiders.

Insmed Company Profile

(Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.